anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a xianglian granule, a xianglian tablet, and preparation methods and applications thereof. The invention provides a xianglian granule which is characterized in that the weight content of the yulian is not less than 6.0 percent calculated by berberine hydrochloride C20H17NO4 & HCl. The invention also provides a preparation method and application of the xianglian granules. For example, the content of the active ingredients of the xianglian tablet prepared by the xianglian granules provided by the invention is obviously improved. The content of Coptidis rhizoma (calculated by berberine hydrochloride C20H17NO4 & HCl) in 0.3g of rhizoma Coptidis is 18.0mg above, which is higher than the existing standard, and is beneficial for further improving and improving therapeutic effect and avoiding inconvenience caused by repeated administration. The preparation method of the xianglian granules is simple and convenient, and the xianglian granules can be prepared into dry granules at one time, so that the heating temperature of the medicine is reduced, the heating time of the medicine is shortened, the content of active ingredients of the medicine is improved, and the product yield is improved.
Grafted cannabis plants and related methods for producing a grafted cannabis plant are provided. In some embodiments, a scion is provided from a first cannabis plant having at least one of a first desired phenotype and a first desired genotype and a rootstock is provided from a second cannabis plant having at least one of a second desired phenotype and a second desired genotype, the rootstock compatible with the scion. The scion may be grafted onto the rootstock to form the grafted plant. In some embodiments, the scion is from a drug-type cannabis plant and the rootstock is from a hemp plant. The grafted cannabis plant may have at least one enhanced plant trait, enhanced harvest trait, and/or emergent property. Related cannabis plant materials and cannabis-derived products are also provided.
Sham stimulation over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered in a continuous train of 40s using a plastic spacer (25mm thickness) between coil and scalp, preventing effective cortical stimulation.
Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
Patients were recruited consecutively based on clinical assessment of risk factors for HF and echocardiographic evidence of systolic dysfunction or diastolic dysfunction. Risk factors for HF were defined as hypertension, atherosclerotic disease, obesity, chronic obstructive lung disease, metabolic syndrome, smoking, and family history of HF. In patients with normal LVEF (\<50), diagnosis of diastolic dysfunction was based on echocardiographic parameters. Chronic lung disease (CLD) was defined as spirometry with obstructive lung disease or restrictive lung disease with accompanying clinical symptoms and signs included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
400 adult smokers will be randomized. Our primary goal is to examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence. All smokers will receive the same "Acute Phase Treatment" that combines nicotine patch, bupropion and intensive self-regulatory skills training. Nicotine patches will be provided for 8 weeks and bupropion and skills training will be provided for of 9 weeks. Participants will then enter a "Maintenance Treatment Phase" during which half (n=200) will receive three individualized relapse prevention training sessions spread over a 12 week period. They will also receive 12 weeks of self-administered RPT administered via written treatment modules. Finally, telephone counseling will be provided in conjunction with an Interactive Voice Response system (IVR) that will allow early detection of smoking "slips" and rapid response by treatment staff. The other half (n=200) will be assigned to a control condition that consists of three counselor-led sessions of "supportive therapy" spread over a 12 week period. P
This is a feasibility and safety study primarily designed to assess the feasibility and safety of conducting a larger clinical trial with sirolimus in individuals with TSC. The present study will employ an ABA design in which three pediatric participants will be selected to receive baseline medical, developmental, behavioral, and cognitive evaluations, followed by a 26 week administration of sirolimus, repeated baseline assessments at the end of the 26 week treatment phase, and a 4 week titrated withdrawal followed by a 22 week period in which no rapalogue is administered. All participants will again be administered baseline medical, behavioral, and cognitive evaluations at the end of the study in order to compare all evaluations done at baseline, the end of the 26 week treatment, and completion of the study. These comparisons will be done to assess secondary outcomes that include reductions in autistic symptoms, self-injury, and aggression, as well as improvements in cognitive function across multiple domains. Furthermore, administration of the secondary outcome measures will also allow us to better understand the sensitivity of these measures in patients with TSC during the course of a clinical trial.

Families of potentially eligible children who express interest in the study and meet prescreening criteria will be invited to attend a screening visit to determine eligibility, inclusion/exclusion criteria, and availability for eight additional study visits. Prior to enrollment, informed consent will be obtained from the parent or legal guardian.

Investigators will use the methods of analysis of single-subject research (ABA design, where first A represents baseline, B represents treatment, and A represents reversal of treatment. The analysis will focus on each of the 3 subjects separately. Data on feasibility and safety (primary outcome) and on frequency of disruptive behavior (secondary outcome) will be plotted and visually inspected to detect any temporal changes by phase: 1. Baseline, 2. Treatment, 3. After treatment. Data in each phase will be summarized as mean +/- standard deviation (SD). We will use the summary data to assess the potential effect of the intervention. Consistency of the effect will be examined across the 3 study participants.
The BFR training program for the intervention group consists of elbow flexion and extension, and knee extension exercises performed with low load (elastic bands; equivalent to 30% 1RM) and concurrent BFR (upper limb 50% AOP; lower limb 60% AOP). Subjects will perform 4 sets (30, 15, 15 and 15 reps) of each exercise with 30 s rest between sets and 5-minute rest between exercises.
BACKGROUND: There exist multiple regulatory layers for point-of-care (POC) testing to be implemented within Australia. This qualitative analysis sought to understand the pre-market barriers and facilitators to scale-up infectious diseases POC testing in primary care settings at the national level.
METHODS: Key informant interviews were undertaken with people (n = 30) working in high- level positions relevant to infectious diseases POC testing in Australia. Participants were recruited from federal and state health departments, industry, and nongovernment national peak bodies. The Unitaid scalability framework informed this analysis to understand barriers and enablers to creating access conditions and establishing country readiness for market access of POC tests.
RESULTS: Participants identified regulatory frameworks as significant barriers to market access. National strategies and advocacy were viewed as potential enablers to establishing country readiness. It was recommended that the national system for universal health care should fund infectious disease POC tests to ensure financial sustainability, though the existing pathology infrastructure was regarded as a likely inhibitor.
CONCLUSIONS: Current regulatory frameworks inhibit market access for infectious disease POC testing devices for use in the primary care setting. National advocacy is urgently needed to gain government support and align national policies with regulatory frameworks.
This is a multicenter randomized phase III trial. The purpose is to evaluate and compare the pathological complete response (pCR) rates after neoadjuvant chemotherapy with tailored chemotherapeutic regimens or standard chemotherapy for stage II/III breast cancer with tumor size more than 2 cm.

For primary operable breast cancer, neoadjuvant chemotherapy is one of standard options. Pathological complete response (pCR) was associated with significantly improved long-term disease free and overall survival. Anthracycline/taxane-based chemotherapy regimens have been studied extensively in prospective trials and are the most frequently prescribed treatments in patients with breast cancer as neoadjuvant chemotherapy. Regimens that have been tested in large multicenter phase III trials and yielded pCR rates of at around 15% and up to 20% after 6 cycles of chemotherapy. Recent evidences have showed that the expression of several proteins in the tumor samples such as tau, topoisomerase II alpha (topo II), and ERCC1 can predict the tumor response to taxanes, anthracyclines, and platinums, respectively. We hypothesized that select chemotherapeutic agent according the expressions of drug sensitivity predictive biomarkers from patient's tumor sample may improve the efficacy of breast cancer treatment.

In this randomized phase III trial, TE (Docetaxel/ epirubicin) will be given in control arm since it is a highly active regimen for breast cancer. In the Tailored chemotherapy arm, 7 different combination chemotherapy regimens that containing 2 drugs among taxotere, epirubicin, cisplatin, vinorelbine, and 5FU, will be given according to the expressions of tumor biomarkers. The doses and schedules of those regimens are selected according published 1st line protocols for breast cancer. The primary endpoint is the pCR rate. After 4 cycles of neoadjuvant chemotherapy, under the assumption of pCR rate of 15% in TE arm, to achieve 80% power at the 5% level (one side) of significance for the detection of a 15% increase of pCR rate in tailored regimen arm, 134 patients in either arm should be included in the study. If a 10% drop-out rate and multi-center study variation effect are considered, totally 316 patients will be required.
Suburban walks will be mapped out in clean, safe streets with sidewalks within 3 miles of the Arboretum, in Chaska, Minnesota. A loop covering approximately 1.25 miles will be mapped. At a usual walking speed of 20 minutes per mile, a subject will complete \~ 2 loops. Each walk will be timed so that walking speed can be included in the statistical analysis as an important covariate.

Nature Walks will take place at the University of Minnesota Landscape Arboretum, which is part of the College of Food, Agricultural and Natural Resource Sciences at the University of Minnesota. The Arboretum features more than 1,215 acres of natural landscapes with over 12 miles of trails. Subjects in this study will take their nature walks on the Green Heron Pond Trail and adjacent trails that can be connected to create a walking loop of \~1.25 miles, or an out-and-back course, matching the distance of the suburban walk. Heron Pond and its adjacent marsh and bog represent three naturally occurring ecosystems in Minnesota that are part of the state's geologic and landscape heritage. The bog trail passes through the most diverse ecotypes of any Arboretum hike. Oak woods, maple woods and the mosaic of intermingled wetlands along the boardwalk offer rich rewards for birders, school groups and families.

The primary approach to the statistical analysis will be a repeated measures multivariable linear regression model. The outcomes will be the psychological and physiological measures of stress. The primary independent variable of interest is condition (suburban v. nature). The interaction of condition and time (week of the study) provides a formal test of intervention effects (differences between the urban and nature walks). That is, over the time course of the interventions, are there significant differences in the outcomes between the urban and nature walks? Covariates to be evaluated in the models as possible confounders include the order of the conditions (urban first v. nature first), age, gender, body mass index, and overall habitual physical activity. On an exploratory basis, the investigators will test whether these covariates also serve as modifiers of the intervention effect.
PCT No. PCT/GB82/00249 Sec. 371 Date Apr. 6, 1983 Sec. 102(e) Date Apr. 6, 1983 PCT Filed Aug. 9, 1982 PCT Pub. No. WO83/00449 PCT Pub. Date Feb. 17, 1983.In a microencapsulation process involving an interfacial polymerization reaction between a compound containing amine groups and a polybasic acid chloride or anhydride, the polymerization being carried out in an emulsion of an aqueous solution in a hydrophobic organic liquid, the reaction is terminated by introducing water into the hydrophobic phase of the emulsion where it reacts with and destroys the residual acid chloride or anhydride.
Chronic myelogenous leukemia (CML) is characterized by the constitutive activation of BCR-ABL tyrosine kinase. Imatinib was approved for CML therapy, however, BCR-ABL-dependent drug resistance, especially BCR-ABL-T315I mutation, restricts its clinical application. In this study, we reported anthraquinone lactone AS1041, a synthesized derivative of marine natural compound Aspergiolide A, showed anti-leukemia effect in vitro and in vivo by promoting cell senescence. Mechanistic study revealed the pro-senescence effect of AS1041 was dependent on oxidative stress-induced DNA damage, and the resultant activation of P53/P21 and P16INK4a/Rb. Also, AS1041 promoted ubiquitin proteasome system (UPS)-mediated BCR-ABL degradation, which also contributed to AS1041-induced senescence. In vivo, AS1041-induced senescence promoted tumor growth inhibition. In summary, the in vitro and in vivo antitumor effect of AS1041 suggests it can serve as a pro-senescence agent for alternative antileukemia therapy and imatinib-resistant cancer therapy by enhancing cellular oxidative stress and BCR-ABL degradation.
BACKGROUND/AIM: As of 2024, anal cancer (AC) has been steadily increasing worldwide but, due to insufficient evidence, anal cancer screening (ACS) has yet to be standardized. Furthermore, most high-risk people in the world have no help paying for it. Therefore, our primary endpoint was to assess the best screening method for these subjects through a provision that was free of charge (all costs were covered by the Italian public health service). Awareness-raising campaign, determination of risk factors, education on anal self-examination, and sampling (ASS) were secondary objectives.
PATIENTS AND METHODS: Screening was on a voluntary basis. Engaging in receptive anal intercourse and having a history of cervical dysplasia were the main inclusion criteria. Level 1 ACS tools included digital ano-rectal examination, anoscopy, anal Pap, and anal human papillomavirus (HPV) DNA test (both through self- and proctologist- sampling); high-resolution anoscopy (HRA) with (HRAB) or without biopsy comprised level 2 screening. High-risk people were enrolled until the available funds were exhausted.
RESULTS: Fifty high-risk people (40 men who had sex with men -MSM-, 9 women, and 1 heterosexual man) were enrolled. AC was found in one HIV-seropositive MSM, high-grade squamous intraepithelial lesion in 10 (20%) MSM, low-grade squamous intraepithelial lesion LSIL in 13 cases (12 MSM and 1 woman). The combination of HRAB and Pap smear screening achieved the highest values for sensitivity, specificity, and accuracy. ASS HPV DNA test provided excellent results comparable to clinician retrieval. Overweight and college education were identified as independent factors for the risk of and prevention of AC, respectively.
CONCLUSION: A free ACS not only appears justified but also recommended to people screened for AC. Excess weight represents a further risk for this population.
PURPOSE:To obtain the maximum antibody titer in a short period by inoculating elastin as an antigen into a chicken, forming the antibody in the body of the chicken, and recovering the material containing the antibody from the blood component. CONSTITUTION:Insoluble elastin is treated and made soluble with enzyme, acid or alkali. The solubilized elastin is inoculated into a chicken together with an immunity enhancing agent by way of subcutaneous injection, abdominal- cavity administration or the like. The amount of the initial inoculation is about 100 - 5,000 mug per chicken. An antibody which is specific to the elastin is formed in the body of the chicken within several weeks from the initial inoculation. In order to keep the high titer of the anti-elastin antibody in the chicken, the elastin having about the same amount as the initially inoculated elastin is additionally inoculated at an interval of 1 - 3 weeks. The blood component of the chicken wherein the anti-elastin antibody is formed in this way is picked up. Thus the blood component containing the material having the antibody that is the intended object to be recovered can be obtained. The maximum antibody titer can be obtained in a short period.
Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
A suspension comprises microgranules of a benzimidazole derivative suspended in an organic solvent, wherein the average diameter of the microgranules is 100 to 1200µm, and wherein the suspension has a standing viscosity of 4000 to 7000 centipoise at 15 to 25oC, and the viscosity of the suspension is 2500 to 4000 centipoise at 15 to 25oC when shaken. Preferably the benzimidazole derivative is selected from omeprazole, pantoprazole, rabeprazole or lansoprazole or mixtures thereof. The benzimidazole derivative is preferably in the form of enteric coated beads wherein the microgranules preferably comprise cores with the benimidazole derivative disposed on the surface thereof. Preferably the core comprises sugar. Preferably the enteric coating comprises a layer comprising a disintegrant, a sealing layer and/or a control release layer. The disintegrant is preferably sodium starch glycolate, the sealing layer is preferably hydroxypropyl methylcellulose, and the control release layer is preferably methacrylic acid and/or ethyl acrylate or copolymers thereof. Preferably the organic solvent is a mixture is triglyceride esters of fatty acids. The suspension is preferably for use in the treatment of dyspepsia, peptic ulcer disease, gastritis, gastroesophageal reflux disease, laryngopharyngeal reflux, gastric and duodenum ulceration and/or Zollinger-Ellison syndrome.
Embodiments of the present invention provide for assessing the state of an <sup>82</sup>Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of <sup>82</sup>Rb, <sup>82</sup>Sr, or <sup>85</sup>Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a <sup>82</sup>Sr/<sup>82</sup>Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the <sup>82</sup>Rb elution system. Further, in response to determining that a total volume of the fluid exceeds a limit threshold, elution is prevented until the generator is replaced with a new generator.
The present invention relates the device and the method for providing a guidance signal. The device preferably relates to a mobile device, such as a mobile tablet computer. The device comprises an input unit, a display and a processing unit. Via the input unit, a three-dimensional outline image of a surface of a human subject is provided, e.g. acquired by a camera. The device further comprises a memory. The memory stores a human reference model, which statistically represents a virtual human subject. In practice it is often the case that the surface outline represented by the human reference model would not instantly fit to the surface outline of the human subject. Therefore, the processing unit is configured to adapt the human reference model resulting in an adapted model, such that the surface outline represented by the adapted model fits to the surface outline of the (real) human subject. Furthermore, the image is acquired as a so-called track-image of an ultrasonic handheld transducer in front of the human subject. The processing unit is configured to recognize the ultrasonic handheld transducer in the track-image and to determine the transducer pose based thereon. In practice, the ultrasonic handheld transducer is to be arranged on the surface of the human subject at a target pose in order to scan a desired scan region of the human subject. The scan region may relate to an inner organ of the human subject. Based on the actual transducer pose and the desired target pose, the processing unit is configured to determine a guidance signal, which indicates how to move and/or rotate the ultrasonic handheld transducer to reach the desired target pose.
Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
Nicotinamide riboside 3000mg daily for the duration of the trial (4 weeks). Administered in tablet form in doses of 1500mg twice daily.
AIM: Sarcopenic obesity (SO) is characterized by the coexistence of the loss of muscle mass and function with excess adipose tissue. Its prevalence has increased concomitantly with population aging, becoming one of the most significant challenges for public health, threatening the quality of life and the physical and mental health of the elderly population.
METHODS: This study estimated the prevalence and factors associated with SO among adults and the elderly in Brazil's macro-regions, utilizing MEDLINE, Embase, Web of Science, and the Virtual Health Library databases. Primary outcomes included SO prevalence overall and by subgroups, with secondary outcomes identifying associated factors.
RESULTS: A systematic review of 33 studies with 10 266 participants up to July 2023 showed a 17% prevalence of SO (95% confidence interval: 13-21%), using a random effects meta-analysis. The Central-West region had the highest occurrence (27%). Dual-energy X-ray absorptiometry (26%) and bioimpedance (6%) were the top diagnostic methods. Protective factors were chronic kidney disease and healthy lifestyles; risk factors included socioeconomic status, functionality, lifestyle, biochemical parameters, and comorbidities such as osteoarthritis and apnea.
CONCLUSIONS: The prevalence of SO in Brazil is significant, emerging as a critical public health problem. It is essential to direct attention to changes in prevalence rates in the coming years, given the rising obesity trends and the absolute increase in the elderly population. Geriatr Gerontol Int 2024; 24: 661-674.